Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas

Richard I. Fisher, Thomas P Miller, Bruce W. Dana, Stephen E. Jones, Steven Dahlberg, Charles A. Coltman

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Previous studies have established CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) as the standard of comparison for treatment programs for patients with advanced stages of aggressive non-Hodgkin's lymphomas. Three sequential CHOP studies conducted by the Southwest Oncology Group (SWOG) showed a complete remission (CR) rate of 53% for 418 patients. This rate did not vary among the three studies. Median age was over 55 years. Relapse-free survival of CRs plateaued at 4 to 5 years. Approximately 21% of all patients in the first study and 33% of all patients in the following two studies are long-term survivors and presumed cured. Survival was clearly a function of patient age. Approximately 45% of all patients under age 55 at the time of treatment are cured by CHOP chemotherapy. To determine the toxicity, CR rate, and patient survival of m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), ProMACE-CytaBOM (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate), and MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), SWOG initiated a series of phase II studies. Of 118 eligible patients in the m-BACOD study, the median age of 85 patients treated with the full-dose regimen was 54 years, while the median age of 33 patients who started therapy at reduced doses was 67 years. Fatal toxicity was observed in 6% of patients receiving full doses and 13% of those receiving reduced doses. Life-threatening toxicity occurred in 31% of patients on the full-dose regimen and 34% on the reduced-dose regimen. CR was 65% for full-dose treatment, but 27% for reduced doses. Of the 83 evaluable patients in the ProMACE-CytaBOM study, the median age was 54 years. Fatal toxicity was observed in 5% of all patients, and life-threatening toxicity occurred in 16%. CR rate in 79 patients evaluated for response is 58%. Results from 131 patients entered into the MACOP-B study are currently being analyzed. A large-scale, randomized comparative study of these four treatment programs was recently undertaken to determine if the newer regimens are superior to standard CHOP therapy and how they compare with each other in terms of toxicity, cost, and therapeutic effectiveness.

Original languageEnglish (US)
Pages (from-to)21-25
Number of pages5
JournalSeminars in Hematology
Volume24
Issue number2 SUPPL. 1
StatePublished - Apr 1987

Fingerprint

Non-Hodgkin's Lymphoma
Clinical Trials
Methotrexate
Vincristine
Doxorubicin
Cyclophosphamide
Bleomycin
Prednisone
Cytarabine
Etoposide
Therapeutics
Survival
Dexamethasone
Cost-Benefit Analysis
Survivors
Survival Rate

ASJC Scopus subject areas

  • Hematology

Cite this

Fisher, R. I., Miller, T. P., Dana, B. W., Jones, S. E., Dahlberg, S., & Coltman, C. A. (1987). Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas. Seminars in Hematology, 24(2 SUPPL. 1), 21-25.

Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas. / Fisher, Richard I.; Miller, Thomas P; Dana, Bruce W.; Jones, Stephen E.; Dahlberg, Steven; Coltman, Charles A.

In: Seminars in Hematology, Vol. 24, No. 2 SUPPL. 1, 04.1987, p. 21-25.

Research output: Contribution to journalArticle

Fisher, RI, Miller, TP, Dana, BW, Jones, SE, Dahlberg, S & Coltman, CA 1987, 'Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas', Seminars in Hematology, vol. 24, no. 2 SUPPL. 1, pp. 21-25.
Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA. Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas. Seminars in Hematology. 1987 Apr;24(2 SUPPL. 1):21-25.
Fisher, Richard I. ; Miller, Thomas P ; Dana, Bruce W. ; Jones, Stephen E. ; Dahlberg, Steven ; Coltman, Charles A. / Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas. In: Seminars in Hematology. 1987 ; Vol. 24, No. 2 SUPPL. 1. pp. 21-25.
@article{caecc3ea6f0d46bd9139779c277a43d5,
title = "Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas",
abstract = "Previous studies have established CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) as the standard of comparison for treatment programs for patients with advanced stages of aggressive non-Hodgkin's lymphomas. Three sequential CHOP studies conducted by the Southwest Oncology Group (SWOG) showed a complete remission (CR) rate of 53{\%} for 418 patients. This rate did not vary among the three studies. Median age was over 55 years. Relapse-free survival of CRs plateaued at 4 to 5 years. Approximately 21{\%} of all patients in the first study and 33{\%} of all patients in the following two studies are long-term survivors and presumed cured. Survival was clearly a function of patient age. Approximately 45{\%} of all patients under age 55 at the time of treatment are cured by CHOP chemotherapy. To determine the toxicity, CR rate, and patient survival of m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), ProMACE-CytaBOM (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate), and MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), SWOG initiated a series of phase II studies. Of 118 eligible patients in the m-BACOD study, the median age of 85 patients treated with the full-dose regimen was 54 years, while the median age of 33 patients who started therapy at reduced doses was 67 years. Fatal toxicity was observed in 6{\%} of patients receiving full doses and 13{\%} of those receiving reduced doses. Life-threatening toxicity occurred in 31{\%} of patients on the full-dose regimen and 34{\%} on the reduced-dose regimen. CR was 65{\%} for full-dose treatment, but 27{\%} for reduced doses. Of the 83 evaluable patients in the ProMACE-CytaBOM study, the median age was 54 years. Fatal toxicity was observed in 5{\%} of all patients, and life-threatening toxicity occurred in 16{\%}. CR rate in 79 patients evaluated for response is 58{\%}. Results from 131 patients entered into the MACOP-B study are currently being analyzed. A large-scale, randomized comparative study of these four treatment programs was recently undertaken to determine if the newer regimens are superior to standard CHOP therapy and how they compare with each other in terms of toxicity, cost, and therapeutic effectiveness.",
author = "Fisher, {Richard I.} and Miller, {Thomas P} and Dana, {Bruce W.} and Jones, {Stephen E.} and Steven Dahlberg and Coltman, {Charles A.}",
year = "1987",
month = "4",
language = "English (US)",
volume = "24",
pages = "21--25",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - Southwest oncology group clinical trials for intermediate-and high-grade non-hodgkin's lymphomas

AU - Fisher, Richard I.

AU - Miller, Thomas P

AU - Dana, Bruce W.

AU - Jones, Stephen E.

AU - Dahlberg, Steven

AU - Coltman, Charles A.

PY - 1987/4

Y1 - 1987/4

N2 - Previous studies have established CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) as the standard of comparison for treatment programs for patients with advanced stages of aggressive non-Hodgkin's lymphomas. Three sequential CHOP studies conducted by the Southwest Oncology Group (SWOG) showed a complete remission (CR) rate of 53% for 418 patients. This rate did not vary among the three studies. Median age was over 55 years. Relapse-free survival of CRs plateaued at 4 to 5 years. Approximately 21% of all patients in the first study and 33% of all patients in the following two studies are long-term survivors and presumed cured. Survival was clearly a function of patient age. Approximately 45% of all patients under age 55 at the time of treatment are cured by CHOP chemotherapy. To determine the toxicity, CR rate, and patient survival of m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), ProMACE-CytaBOM (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate), and MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), SWOG initiated a series of phase II studies. Of 118 eligible patients in the m-BACOD study, the median age of 85 patients treated with the full-dose regimen was 54 years, while the median age of 33 patients who started therapy at reduced doses was 67 years. Fatal toxicity was observed in 6% of patients receiving full doses and 13% of those receiving reduced doses. Life-threatening toxicity occurred in 31% of patients on the full-dose regimen and 34% on the reduced-dose regimen. CR was 65% for full-dose treatment, but 27% for reduced doses. Of the 83 evaluable patients in the ProMACE-CytaBOM study, the median age was 54 years. Fatal toxicity was observed in 5% of all patients, and life-threatening toxicity occurred in 16%. CR rate in 79 patients evaluated for response is 58%. Results from 131 patients entered into the MACOP-B study are currently being analyzed. A large-scale, randomized comparative study of these four treatment programs was recently undertaken to determine if the newer regimens are superior to standard CHOP therapy and how they compare with each other in terms of toxicity, cost, and therapeutic effectiveness.

AB - Previous studies have established CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) as the standard of comparison for treatment programs for patients with advanced stages of aggressive non-Hodgkin's lymphomas. Three sequential CHOP studies conducted by the Southwest Oncology Group (SWOG) showed a complete remission (CR) rate of 53% for 418 patients. This rate did not vary among the three studies. Median age was over 55 years. Relapse-free survival of CRs plateaued at 4 to 5 years. Approximately 21% of all patients in the first study and 33% of all patients in the following two studies are long-term survivors and presumed cured. Survival was clearly a function of patient age. Approximately 45% of all patients under age 55 at the time of treatment are cured by CHOP chemotherapy. To determine the toxicity, CR rate, and patient survival of m-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone), ProMACE-CytaBOM (prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, bleomycin, vincristine, methotrexate), and MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin), SWOG initiated a series of phase II studies. Of 118 eligible patients in the m-BACOD study, the median age of 85 patients treated with the full-dose regimen was 54 years, while the median age of 33 patients who started therapy at reduced doses was 67 years. Fatal toxicity was observed in 6% of patients receiving full doses and 13% of those receiving reduced doses. Life-threatening toxicity occurred in 31% of patients on the full-dose regimen and 34% on the reduced-dose regimen. CR was 65% for full-dose treatment, but 27% for reduced doses. Of the 83 evaluable patients in the ProMACE-CytaBOM study, the median age was 54 years. Fatal toxicity was observed in 5% of all patients, and life-threatening toxicity occurred in 16%. CR rate in 79 patients evaluated for response is 58%. Results from 131 patients entered into the MACOP-B study are currently being analyzed. A large-scale, randomized comparative study of these four treatment programs was recently undertaken to determine if the newer regimens are superior to standard CHOP therapy and how they compare with each other in terms of toxicity, cost, and therapeutic effectiveness.

UR - http://www.scopus.com/inward/record.url?scp=0023322337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023322337&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 21

EP - 25

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2 SUPPL. 1

ER -